Background-T cells play an important role during the immune response that accompanies atherosclerosis. To date, the role for interleukin (IL)-17A in atherogenesis is not well defined. Here, we tested the hypothesis that atherosclerosisprone conditions induce the differentiation of IL-17A-producing T cells, which in turn promote atherosclerosis. Methods and Results-IL-17A was found to be elevated in the plasma and tissues of apolipoprotein E-deficient (Apoe 
A therosclerosis is the leading cause of cardiovascular disease worldwide. Defined as chronic inflammation of the artery wall, its progression from fatty streaks to more complex lesions and plaque rupture involves a complicated interplay between many different cell types and cytokine networks. Both innate and adaptive immune responses have been shown to regulate local and systemic inflammation during atherogenesis. 1,2 T cells are found within the adventitia of normal/noninflamed vessels as a result of a constitutive T-cell homing into the aorta. 3 Atherosclerosis-prone conditions accelerate T-cell recruitment into the aorta of apolipoprotein E-deficient (Apoe Ϫ/Ϫ ) mice in both the early and advanced stages of atherosclerosis. 3 The majority of aortic T cells are T-cell receptor ␣␤ ϩ CD4 ϩ cells, with few CD8 ϩ and ␥␦ ϩ T cells present. 1, 4 Of the CD4 ϩ T cells, T helper 1 (Th1) cells predominate over T helper 2 (Th2) cells during early lesion formation and respond with an elevated production of interferon (IFN)-␥ and interleukin (IL)-6. In the later stages of the disease, a switch to a Th2 response and IL-4 production is evident in the atherosclerotic lesions of Apoe Ϫ/Ϫ mice. 5 
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IL-17A is a member of the IL-17 family, which includes IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. 6 Many lymphocyte subsets secrete IL-17A in response to cytokine or monoclonal antibody stimulation, including CD4 ϩ ␣␤ ϩ (Th17 cells) CD8 ϩ , CD4 Ϫ CD8 Ϫ ␣␤ low , natural killer T cells, and ␥␦ ϩ T cells. 7 The expression of IL-17A is low under normal/noninflamed conditions, in which ␥␦ ϩ T cells are the largest IL-17A-producing T-cell subset. 6 In several murine models of autoimmune diseases, including multiple sclerosis, inflammatory bowel disease, and arthritis, serum IL-17A levels are elevated, and the T helper 17 (Th17) cell population is expanded and plays a highly pathogenic role. 8 Conversely, IL-17A is a protective cytokine in host responses against extracellular pathogens through the induction of proinflammatory cytokines such as IL-6, tumor necrosis factor-␣, and granulocyte colony-stimulating factor (G-CSF) and the chemokines CXCL8, CCL2, CXCL1, and CXCL2 in infected tissues. 6 These downstream mediators of IL-17A are involved in granulopoiesis and induce the recruitment of neutrophils, eosinophils, and monocytes into sites of inflammation. 9 To date, the contribution of IL-17A to atherogenesis remains controversial, with different studies proposing either a proatherogenic or an atheroprotective role for IL-17A. In patients with unstable angina, levels of plasma IL-17A and the Th17-related cytokines IL-6 and IL-23 are elevated. 10 Cultured human T cells isolated from atherosclerotic coronary arteries also produce a unique combination of IL-17A and IFN-␥ after polyclonal stimulation compared with T cells extracted from nondiseased vessels. 11 In murine models of atherosclerosis, deletion of IL-18 in Apoe Ϫ/Ϫ mice results in an increase in Th17 cells within the aorta and exacerbated atherosclerosis. 12 Additionally, the absence of IL-17 receptor A (IL-17RA) on bone marrow-derived cells in lethally irradiated LDL receptor (Ldlr)-deficient mice also reduces atheroma formation. 13 Together, these studies suggest a proatherogenic role for IL-17A and IL-17A-producing cells. More recently, a study 14 using intravenous administration of recombinant IL-17A reduced atherosclerosis in young chimeric Ldlr Ϫ/Ϫ mice, which suggests atheroprotection by IL-17A; however, the administration of anti-IL-17A antibodies had no effects on atherosclerosis in this model.
Here, we report that Apoe Ϫ/Ϫ mice have elevated plasma levels of IL-17A and show increased numbers of IL-17A-expressing T cells, in particular Th17 and IL-17A ϩ ␥␦ ϩ T cells, within the aorta (adventitia and intima) and spleen. Blockade of IL-17A by soluble IL-17 receptor A (sIL-17RA) causes a significant decrease in the plasma levels of IL-6 and G-CSF, diminishes aortic macrophage content, reduces aortic CXCL1 expression, and leads to reduced plaque burden in Apoe Ϫ/Ϫ mice. IL-17A treatment of isolated Apoe Ϫ/Ϫ aortas increases CXCL1 expression and monocyte adhesion. Taken together, these results demonstrate a proatherogenic role of IL-17A and highlight a new role for IL-17A-producing T-cell subsets in the progression of atherosclerosis.
Methods

Animals
Female and male Apoe Ϫ/Ϫ mice on a C57BL/6 background and control C57BL/6 mice (Jackson Labs, Bar Harbor, Me), were kept on a chow diet and were used between 40 and 55 weeks of age. Alternatively, Apoe Ϫ/Ϫ mice were fed a Western diet (21% fat and 0.15% cholesterol, Harlan Teklad, Harlan Laboratories, Indianapolis, Ind) for 15 weeks and used at 21 weeks of age. All animals were kept in specific-pathogen-free conditions, and animal experiments were approved by the Animal Care and Use Committees of the University of Virginia and Eastern Virginia Medical School. Blood counts were taken via tail bleed and analyzed with an automatic analyzer (Hemavet 850, CDC Technologies Inc, Oxford, Conn). Additional Methods can be found in the online-only Data Supplement.
Statistical Analysis
For unpaired t tests, data were expressed as meanϮSEM. Statistical significance between Apoe Ϫ/Ϫ and C57BL/6 mouse groups was set at PϽ0.05.
Results
Levels of IL-17A Are Elevated in Apoe
To test the role of IL-17A in the immune response that accompanies advanced atherosclerosis, we analyzed IL-17A messenger RNA (mRNA) within the aorta, spleen, peripheral lymph nodes (including inguinal, axillary, brachial, and cervical nodes), mesenteric lymph nodes, and lamina propria of 40-to 55-week-old female and male Apoe Ϫ/Ϫ and C57BL/6 mice. We chose to study aged Apoe Ϫ/Ϫ mice because they have been shown to develop advanced fibrous plaques at 40 to 45 weeks of age. 15 We found a significant increase in IL-17A expression in the aorta, spleen, peripheral lymph nodes, and lamina propria of Apoe Ϫ/Ϫ mice but not in the mesenteric lymph nodes ( Figure 1A ). Because the IL-17 family consists of 5 additional members (IL-17B, C, D, E, and F), we also examined the mRNA expression of IL-17C, D, E, and F in Apoe Ϫ/Ϫ aortas. IL-17A mRNA expression was found to be approximately 5-fold greater than that of the other IL-17 family members examined ( Figure 1B) . No IL-17E expression was found in aortas isolated from C57BL/6 or Apoe Ϫ/Ϫ mice. Importantly, circulating levels of IL-17A were also elevated in the plasma of aged Apoe Ϫ/Ϫ compared with C57BL/6 mice ( Figure 1C ). Because circulating neutrophil levels correlate closely with plasma IL-17A and G-CSF levels, 9 we analyzed neutrophil numbers in the blood of Apoe Ϫ/Ϫ mice. Circulating neutrophil counts (polymorphonuclear leukocytes) were also significantly elevated in Apoe Ϫ/Ϫ mice compared with C57BL/6 mice ( Figure 1D ); however, no significant difference was seen in the numbers of white blood cells, peripheral blood lymphocytes, or monocytes ( Figure 1D ).
IL-17A induces the release of many chemokines, including CXCL1 and CCL2, as well as tumor necrosis factor-␣, IL-1␤, and IL-6 from monocytes, epithelial cells, and fibroblasts. 6 Circulating levels of tumor necrosis factor-␣ and IL-2 were significantly elevated in Apoe Ϫ/Ϫ mice ( Figure 1C ). Both Th1 (IL-12) and Th2 (IL-4, IL-5, IL-10, and IL-13) cytokines were also elevated in the plasma of Apoe Ϫ/Ϫ mice compared with C57BL/6 mice (online-only Data Supplement Figure IA through IE). We next explored whether atherosclerosis-prone conditions induced elevated IL-17A levels through the SOCS-3 (suppressor of cytokine signaling-3)-dependent pathway. We found no difference in aortic mRNA SOCS-3 expression in 21-week-old Apoe Ϫ/Ϫ mice fed a Western diet or 40-week-old Apoe Ϫ/Ϫ mice fed a chow diet compared with C57BL/6 mice (data not shown).
Th17 and ␥␦ ؉ T Cells Are the Major Producers of IL-17A During Atherosclerosis
As IL-17A was elevated at the RNA and circulating protein level in aged Apoe Ϫ/Ϫ mice, we attempted to identify the cellular source behind its production. Under normal conditions, the number of Th17 cells found in C57BL/6 mice is very small, with the main source of IL-17A-producing T cells being located in the lamina propria. 16, 17 Here, we demonstrate elevated numbers of CD45 ϩ IL-17A ϩ cells in the aorta, lamina propria, and spleen of aged female and male Apoe Ϫ/Ϫ mice compared with C57BL/6 mice ( Figure 2 ). These IL- 3 Here, we demonstrated that approximately 5% to 7% of those cells in aortas were IL-17A-producing T cells. Further characterization of the IL-17A ϩ T cells revealed the presence of IL-17A-producing ␥␦ ϩ T cells and CD4 ϩ (Th17) cells in the aorta and spleen of both Apoe Ϫ/Ϫ and C57BL/6 mice ( Figure 2C , 2D, and 2E). Together, these data demonstrate a large elevation of IL-17A-producing T cells under atherosclerosis-prone conditions and suggest that both Th17 and ␥␦ ϩ T cells may be responsible for the elevated levels of IL-17A seen systemically in Apoe Ϫ/Ϫ mice. Large numbers of CD3 ϩ IL-17A ϩ leukocytes were also present in the aortas and spleen of Apoe Ϫ/Ϫ mice fed a Western diet for 15 weeks compared with CD3 ϩ IL-17A ϩ cells in C57BL/6 mice ( Figure  2B ), although the number of IL-17A ϩ T cells was not significantly different in Apoe Ϫ/Ϫ mice fed a chow or Western diet, which suggests that the atherosclerosis-prone background, rather than diet, is responsible for the induction of IL-17A ϩ cells in vivo. We confirmed these data by reverse-transcription polymerase chain reaction, which also showed a significant increase in IL-17A mRNA expression in aortas isolated from Apoe Ϫ/Ϫ mice fed a Western diet for 15 weeks compared with C57BL/6 aortas (data not shown).
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There are several reports that have demonstrated lymphocyte accumulation in the aortic adventitia in normal 3 and atherosclerotic 3, 18 vessels. To further analyze the location of IL-17A ϩ T cells within the artery, we isolated the surrounding adventitia from the aortas ( Figure 2F ; online-only Data Supplement Figure III ). Flow cytometry on the isolated adventitia and aortas from aged Apoe Ϫ/Ϫ mice showed that IL-17A ϩ cells were present in both the adventitia and, to a lesser extent, the vessel wall ( Figure 2G ).
Blockade of IL-17A Diminishes Atherosclerosis in Ad-IL-17RA:Fc-Treated Apoe ؊/؊ Mice
To identify the role for IL-17A in atherosclerosis, we used a fusion protein composed of the IL-17RA extracellular domain fused with the murine IgG1 CH2 and CH3 domains (Ad-IL-17RA:Fc 19 ) to block circulating IL-17A in Apoe
mice. To express IL-17RA:Fc in vivo, an E1-deleted recombinant adenovirus (Ad-IL-17RA:Fc) was generated. 19 In vivo, these adenoviruses are typically expressed in the liver, and soluble products are detected in the plasma of recipient mice. 20 Ad-IL-17RA:Fc significantly inhibits recombinant IL-17A-induced production of IL-6 by 3T3 fibroblasts. 19 Released sIL-17RA blocks the activities of IL-17A but not IL-17F and acts as a soluble receptor for IL-17A. 21 Importantly, Ad-IL-17RA:Fc does not induce leukocyte activation via surface Fc receptors (data not shown).
We experimentally developed a protocol that allows maintenance of the expression of Ad-IL-17RA:Fc for 15 weeks (online-only Data Supplement Figure II) . To accelerate atherosclerosis development, mice were fed a Western diet. 15 To promote tolerance to the adenovirus and mini- Figure 3A shows the detection of plasma sIL-17RA in 6-week-old Apoe Ϫ/Ϫ mice 7 days after the second injection of Ad-IL-17RA:Fc ( Figure 3A, lanes 1 and 2) . To confirm the expression of control Ad-Lu, we analyzed Ad-Lu expression by bioluminescence imaging (data not shown). sIL-17RA was also detectable in the plasma of Ad-IL-17RA:Fc-recipient mice on the day of termination (Figure 3B ). To confirm that tolerance was maintained in the adenovirus-treated mice, we analyzed IFN-␥ concentration in peripheral blood of recipient mice and found that plasma levels of IFN-␥ did not reach more than Ϸ22 ng/mL in Ad-IL-17RA:Fc-and Ad-Lu-treated recipients ( Figure 4B ). These results suggest that an acute immune response did not occur in the adenovirus-recipient mice cohorts. Apoe Ϫ/Ϫ mice in both groups had comparable levels of triglycerides (186Ϯ28 and 190Ϯ40 mg/dL for Ad-IL-17R-Fc-and Ad-Lu-injected Apoe Ϫ/Ϫ mice, respectively). Interestingly, Apoe To investigate the mechanisms by which the blockade of circulating IL-17A may lead to diminished atherosclerosis, we examined the circulating levels of key proinflammatory cytokines in the plasma of treated Apoe Ϫ/Ϫ mice. We found a significant decrease in IL-6 plasma levels in Ad-IL-17RA:Fc-treated compared with Ad-Lu-treated Apoe Ϫ/Ϫ mice ( Figure 4A ). Previous studies have shown that IL-17A drives the production of G-CSF, which is directly responsible for the differentiation and proliferation of neutrophil precursors in the bone marrow. 9 Therefore, we hypothesized that inhibition of IL-17A may lead to decreased levels of G-CSF in Ad-IL17-RA:Fc-treated mice. As shown in Figure 4C , we detected diminished levels of G-CSF in the plasma of Ad-IL17-RA:Fc-treated compared with Ad-Lu-treated Apoe Ϫ/Ϫ mice. These data confirm that sIL-17RA neutralized plasma IL-17A activity and as a consequence decreased G-CSF production, which in turn may have lowered blood neutrophil numbers. Ad-IL-17RA:Fc treatment did not affect circulating IL-17F plasma levels in Apoe Ϫ/Ϫ recipient mice compared with Apoe Ϫ/Ϫ mice that received Ad-Lu ( Figure 4D ).
IL-17A Regulates Macrophage Accumulation Within Aortas of Apoe ؊/؊ Mice via a CXCL1-Dependent Mechanism
IL-17A promotes inflammation by the induction of proinflammatory chemokines such as CCL2 and CXCL1, which To further test the hypothesis that IL-17A is involved in the regulation of monocyte adhesion/migration, we performed ex vivo monocyte adhesion assays using IL-17A-treated or vehicle-treated isolated Apoe Ϫ/Ϫ aortas. We detected increased adhesion of CFSE-labeled monocytes to the IL-17A-treated luminal aortic wall in the presence of IL-17A compared with vehicle-treated aortas ( Figure 5E and 5F). Interestingly, elevated monocyte adhesion was also detected when both monocytes and isolated aortas were treated with IL-17A ( Figure 5E and 5F). To determine whether the differences in monocyte adhesion could be explained by the induction of CXCL1, we further analyzed the aortas for CXCL1 expression by reversetranscription polymerase chain reaction and detected a significant increase in CXCL1 expression in both IL-17A-treated monocytes/aortas and IL-17A-treated aortas compared with vehicle-treated aortas ( Figure 5G ). Together, these results suggest that IL-17A can activate vascular cells, induce CXCL1 production, and further accelerate monocyte recruitment into the aortic wall. In addition to this effect, IL-17A elevates monocyte adhesion through activation of monocytes in peripheral circulation. 
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The present study reveals that IL-17A-producing T cells are present in the aortas of C57BL/6 mice, and their numbers are greatly elevated under the atherosclerosis-prone conditions found in Apoe Ϫ/Ϫ mice fed either a chow or Western diet. Interestingly, not only Th17 but also ␥␦ ϩ T cells are a source of IL-17A within atherosclerosis-prone aortas. The adenovirus-mediated blockade of IL-17A resulted in reduced plasma levels of IL-6 and G-CSF and diminished plaque burden, with a concomitant reduction of aortic macrophages and CXCL1. Moreover, IL-17A elevated CXCL1-dependent monocyte adhesion to isolated aortas ex vivo. Thus, we demonstrate a proatherogenic role for IL-17A in the development of atherosclerosis in mice.
The association of IL-17A with human autoimmune diseases has been shown extensively in patients with rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and psoriasis. 8 A growing body of evidence also suggests that IL-17A might be involved in the immune response during atherosclerosis. 10, 11, 14, 22 Soluble levels of IL-17A are elevated during the onset of acute coronary syndrome compared with stable angina 10 and in a subset of aged patients with coronary atherosclerosis and referent outpatients. 11 Recently, Xie et al 23 reported elevated levels of IL-17A in the plasma of Apoe Ϫ/Ϫ mice at 8 to 16 weeks of age. Here, we have confirmed and extended these results and demonstrated elevated levels of plasma IL-17A in 40-to 50-week-old Apoe Ϫ/Ϫ mice with a concomitant increase in IL-2, IL-6, and tumor necrosis factor-␣. We also found that IL-17A was the most prevalent cytokine of the IL-17 family in Apoe Ϫ/Ϫ mice. Indeed, the number of IL-17A
ϩ T cells was increased in the artery wall, spleen, and lamina propria of aged Apoe Ϫ/Ϫ mice, which suggests that systemic inflammation found in Apoe Ϫ/Ϫ mice may initiate the differentiation of IL-17A-producing T cells in secondary lymphoid and nonlymphoid tissues. Recent reports have indicated an important role of adventitia in atherogenesis. 1, 24 Most CD3 ϩ cells are located within the aortic adventitia of atherosclerosis-prone Apoe Ϫ/Ϫ mice. 3, 18 The present study clearly identified IL-17A-producing T cells by flow cytometry and reverse-transcription polymerase chain reaction on preparations of total aorta that included artery wall and surrounding adventitia. Using flow cytometry on the aortic adventitia, we also demonstrated that IL-17A ϩ T cells are located in the adventitia and within the aortic intima of Apoe Ϫ/Ϫ mice. The roles of leukocytes that reside in different locations during atherogenesis are not well understood, and further studies will identify the specific role of IL-17A ϩ cells in these 2 different sites. Recently, a study by Eid et al 11 showed that CD4 ϩ cells isolated from human atherosclerotic coronary arteries produce IL-17A and IFN-␥ in response to polyclonal stimulation in vitro. In the present report, we further examined the phenotype of IL-17A ϩ cells and demonstrated that not only Th17 cells but also IL-17A ϩ ␥␦ ϩ T cells were significantly elevated in atherosclerosis-prone murine aortas. The mechanisms behind human and murine Th17 cell differentiation are well established in vitro; however, little information is available about the induction of IL-17A ϩ cells during chronic inflammation in vivo. SOCS-3 is involved in the preferential promotion of Th17 cell induction. 25 Interestingly, we found no significant changes in SOCS-3 expression between the aortas of C57BL/6 and Apoe Ϫ/Ϫ mice. These preliminary findings suggest that IL-17A is likely upregulated independently of SOCS-3 in atherosclerosis-prone conditions. Further studies are necessary to determine the mechanisms behind IL-17A induction in atherosclerosis. Recently, CD27 was identified as a thymic determinant of the balance between IFN-␥ and IL-17A-producing ␥␦ ϩ T-cell subsets. 26 
␥␦
ϩ T cells also express ROR␥ and produce IL-17A, IL-21, and IL-22 in response to IL-1␤ and IL-23, without T-cell receptor engagement. 27 The existence of an expanded IL-17A
ϩ ␥␦ ϩ T-cell population in Apoe Ϫ/Ϫ mice suggests at least Ϫ/Ϫ mice and treated with IL-17A as described in Methods. Fluorescently labeled monocytes (green) were added to aortas for an adhesion assay, and adherent monocytes were counted by blinded observers using a fluorescent microscope. F, Data represent meanϮSE of 3 to 4 counted aortas per group from 4 independent experiments. G, Aortic mRNA expression. Total cellular RNA from vehicle-treated (white bars), IL-17A-treated (gray bars), and unwashed IL-17A-treated (black bars) aortas were examined for CXCL1 by quantitative reversetranscription polymerase chain reaction. *PϽ0.05, **PϽ0.01, ***PϽ0.001 by Student t test with Bonferroni-Holm correction for multiple comparison (for Figure 5F and 5G). Data are from 3 independent experiments using 3 to 4 aortas per group. RQ value indicates relative quantification; Mn, monocyte.
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partial T-cell receptor-independent upregulation of IL-17A during atherosclerosis. Further studies will be necessary to investigate the mechanisms of induction of IL-17A ϩ T cells during atherogenesis.
There are several pathways by which IL-17A might affect local inflammation. IL-17A induces the production of cytokines and chemokines in several cell types, including endothelial and vascular smooth muscle cells. 28, 29 IL-17A and IFN-␥ synergistically initiate production of IL-6, CXCL8, CCL5, CXCL1, and CXCL10 in cultured vascular smooth muscle cells. 11 CXCL1 is a chemokine that triggers monocyte arrest on endothelium during atherogenesis and thus plays a critical role in monocyte recruitment into artery wall. 30 Monocytes express IL-17RA on their surface, and recent data suggest that IL-17A can also directly affect monocyte chemotaxis in vivo and in vitro. 31, 32 Antibody blockade of IL-17A in the synovial fluid of rheumatoid arthritis patients inhibits monocyte migration in vitro, as well as macrophage accumulation in the bronchoalveolar lavage fluid during allergic airway inflammation. 31, 32 The role of IL-17A and IL-17A-expressing T cells in atherosclerosis remains unclear. Several studies with conflicting results have been published, and more research on the role of the IL-17A-dependent response in atherosclerosis is warranted. The present study for the first time characterizes the subpopulations of T cells that express IL-17A in atherosclerosis and highlights a possible role of IL-17A in the regulation of monocyte migration into aortas. We report that blockade of IL-17A in vivo leads to decreased CXCL1 expression within atherosclerosis-prone aortas and diminished aortic macrophage content. We also demonstrate the proinflammatory role of IL-17A in the regulation of monocyte migration into the aortas via ex vivo monocyte adhesion assay. Together, these results indicate that IL-17A contributes to the pathogenesis of atherosclerosis at least through the regulation of monocyte recruitment to the aortic wall via CXCL1 expression on the vessel lumen. It remains to be determined whether IL-17A also activates monocytes/macrophages within the plaque to induce the synthesis of tumor necrosis factor-␣, IL-1␤, IL-6, CXCL2, and granulocyte macrophage colony-stimulating factor and further perpetuate inflammation.
IL-17A regulates levels of G-CSF in circulation and thus affects neutrophil numbers in the blood. We detected decreased levels of G-CSF in the plasma of Apoe Ϫ/Ϫ mice that received Ad-IL-17RA:Fc. It would be important to investigate the role of IL-17A-dependent involvement of neutrophils in atherogenesis. To further understand the effect of the cytokine profile on blockade of IL-17A, we also analyzed plasma levels of IL-17F, a cytokine that can compensate for a deficiency in IL-17A in Il-17a Ϫ/Ϫ mice. 33 We found no difference between Ad-IL-17RA:Fc-and Ad-Lu-treated groups of mice, which suggests that neutralization of IL-17A is not enough to induce compensatory elevation of IL-17F in Apoe Ϫ/Ϫ mice. Regulation of Th17 cell differentiation by IFN-␥ has been shown in vitro, 8 and implicates the Th1 cytokines as potent inhibitors of Th17 cell differentiation; however, a population of cells that secrete both IFN-␥ and lL-17A can be detected among cells isolated from inflammatory conditions in vivo. 34 -36 To date, it is unclear whether IL-17A can regulate the Th1 response in vivo. The results of the present study demonstrate that blockade of IL-17A with sIL-17RA has no effect on levels of plasma IFN-␥ in Apoe Ϫ/Ϫ mice. Further studies will be necessary to explore the complex relationship between Th1 and Th17 cell differentiation programs in vivo.
In summary, the discovery of IL-17A-producing Th17 and ␥␦ ϩ T cells and their proatherogenic properties challenges the Th1 and Th2 paradigm thought to be involved in the adaptive immune response of cardiovascular disease. The present findings suggest a new IL-17A-dependent pathway by which the immune system may influence the development and progression of atherosclerosis. Flow cytometry. Single cell suspensions from the aorta and surrounding adventitia were prepared as previously described. 1 Briefly, mice were anesthetized, and their vasculature was perfused by cardiac puncture with phosphate-buffer saline (PBS) containing 20 units/ml of heparin. Harvested aortas were microdissected and digested with 125 U/ml collagenase type XI, 60 U/ml hyaluronidase type I-s, 60 U/ml DNAse1 and 450 U/ml collagenase type I (all enzymes Sigma, St. Louis, MO) in PBS at 37 o C for 1 hour. 1 Single cell suspensions from spleen, mesenteric lymph nodes (MLN), peripheral LN (PLN), lamina propria (LP) 2 and aortas were treated with 10 ng/ml PMA, 500 ng/ml calcium ionophore and GolgiStop for 5 h. Intracellular staining for IL-17A and CD4 was performed using Fix&Perm® cell permeabilization reagents.
In some experiments, 1-2 aortas were pooled for the intracellular staining. To determine the location of IL-17-expressing cells, harvested aortas with surrounding adventitia were digested with 312.5 U/ml collagenaseII and 5.625 U/ml elastase (Worthington Biochemical Corp., Lakewood, NJ) for 1 hr at 37°C, and adventitia was carefully removed. Aortas and the adventitia were further digested separately for 30 min at 37°C. Cell suspensions from pooled 3-4 aortas were treated as described above. Flow cytometry analysis was performed on a FACSCalibur TM or CyanADP TM , data analyzed using FlowJO (Tree Star Inc., Ashland, OR) software. Gates were set by isotype controls or fluorescent minus one control.
